Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Articles|October 25, 2013

Customizing the IOL experience

Choosing and using the AcrySof IQ ReSTOR IOL family - Customized options for individual patients.

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Related Content

Real-World Outcomes of a Spiral Optic IOL Compared with a Diffractive Trifocal

ByJames Myerscough, MD

August 1st 2026

Necessity-Driven Innovation - A Personal Journey Toward Efficient and Controlled 27-Gauge Vitrectomy

ByMitrofanis Pavlidis, MD, PhD

August 1st 2026

Staying at the top: Optimizing clinical care and practice efficiency with multimodal Triton imaging

Early Clinical Impressions of the Triton2 and IMAGEnet7® Understanding the Value of Swept-Source OCT Combined with High Quality Colour Fundus Imaging

April 14th 2026

EYLEA 8mg in RVO: QUASAR clinical perspectives video

March 3rd 2026

EYLEA 8mg in RVO: snapshot of the 64-week QUASAR data

March 3rd 2026

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Treatment Optimization in the Evolving Anti-VEGF Era

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery